SiRNA micelle formed based on lipoic acid as well as preparation method and application of siRNA micelle
By using siRNA micelles based on lipoic acid, and taking advantage of the biocompatibility and hydrophilic/hydrophobic properties of lipoic acid, spherical nucleic acid nanoparticles are self-assembled, solving the problems of unclear structure and toxicity of polymeric SNA nanomaterials in the clinical translation process, and realizing the efficient delivery and therapeutic effect of siRNA in brain diseases.
Patent Information
- Application Number
- CN202411033092.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-15
AI Technical Summary
Existing polymeric SNA nanomaterials prepared from polymeric materials face challenges in clinical translation, including unclear structure, molecular weight dispersion, and non-degradability. These issues make it difficult to effectively cross the blood-brain barrier (BBB) to deliver siRNA drugs, and traditional carriers such as lipid nanoparticles pose toxicity risks.
Using siRNA micelles based on lipoic acid (LA), spherical nucleic acid nanoparticles are self-assembled in an aqueous environment through click chemistry. The biocompatibility and hydrophilic/hydrophobic properties of lipoic acid enable efficient delivery of siRNA, which crosses the BBB via scavenger receptor-mediated delivery.
This study achieved highly efficient targeted delivery of siRNA in the treatment of brain diseases, demonstrating antioxidant and anti-inflammatory effects, a well-defined structure, reduced immune response, and improved the feasibility and safety of clinical translation.
Smart Images

Figure CN118948762A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicine, and in particular relates to siRNA micelles formed based on lipoic acid, and a preparation method and application thereof. Background Art
[0002] Glioblastoma (GBM) is a tumor originating from glial cells of the nervous system. It is the dominant and highly invasive primary brain tumor in adults and the most common malignant primary brain tumor, accounting for about 45.2% of all tumors of the central nervous system. It is characterized by cellular heterogeneity and invasion of the entire brain, so it is incurable. Existing treatment methods of surgical resection combined with adjuvant radiotherapy and chemotherapy cannot significantly improve the prognosis and median survival of patients. The poor effect of chemotherapy is largely due to their poor permeability of the blood-brain barrier (BBB), and the drug accumulation concentration in the tumor tissue is difficult to reach an effective therapeutic concentration. Therefore, it is very important to develop other more effective treatment methods.
[0003] In recent years, the incidence of neurodegenerative diseases has increased year by year. Parkinson's disease (PD) is the second largest neurodegenerative disease after Alzheimer's disease. It progresses slowly, has a high incidence in people over 65 years old, has a high disability rate, and the incidence rate is increasing year by year. At present, there is no effective treatment for PD. Most treatments can only slow down the progression of the disease but cannot cure PD. Therefore, new drugs need to be developed to solve the treatment problem of PD. BBB is also a major obstacle in the treatment of PD.
[0004] The BBB is a highly selective semipermeable membrane composed of vascular endothelial cells, pericytes, astrocytes and basement membranes. Its main function is to regulate the exchange of substances between the blood and the central nervous system according to the physiological needs of the brain. The selectivity of the BBB limits the penetration of most chemotherapeutic drugs and biotech drugs. Therefore, the existence of the BBB poses a challenge to the development of therapeutic drugs for brain diseases.
[0005] Traditional therapeutic drugs cannot cross the BBB and have difficulty reaching brain tissue to exert their therapeutic effects. For example, the brain accumulation of hydrophilic small molecules and macromolecular biologics (such as siRNA / mRNA, monoclonal antibodies, and antibody-drug conjugates) is significantly blocked by the BBB. Therefore, the existence of the BBB is a double-edged sword for the treatment of brain diseases. In order to improve the treatment and prognosis of GBM, it is very important to enhance drug penetration across the BBB.
[0006] In recent years, with the in-depth study of the corresponding mechanisms of the occurrence and development of brain tumors and some neurodegenerative diseases at the genetic level, gene drug therapy has attracted increasing attention. Nucleic acid drugs such as small interfering RNA (siRNA) are the third generation of drugs after small molecule drugs and antibodies, with the advantages of strong specificity, high therapeutic efficiency, low toxicity and side effects, simple screening process and wide application field. siRNA can specifically silence genes encoding pathogenic proteins and can provide a new means for the treatment of brain diseases such as GBM and PD. However, siRNA has limitations in the application of in vivo treatment, such as difficulty in resisting nuclease degradation, short half-life, poor tissue penetration and inefficient cell uptake. Therefore, it is necessary to develop effective delivery carriers.
[0007] Nanoparticles improve the pharmacokinetics of nucleic acid drugs, delivering nucleic acid drugs at therapeutic concentrations while maximally protecting them from degradation. Nanoparticles that can reduce nonspecific immune responses are being actively studied and clinically tested.
[0008] The earliest carrier developed for siRNA delivery was lipid nanoparticle (LNP). The emergence of LNP was an important milestone in nucleic acid drug delivery. However, some cationic liposomes are more likely to cause dose-dependent toxicity and can cause lung inflammation and toxicity by inducing the release of reactive oxygen intermediates (ROI).
[0009] The GaLNAc conjugate delivery system can specifically target the liver, with low dosage, long-lasting efficacy and few side effects. However, its limitation is that it can only target the liver. siRNA drugs targeting different organs are still in clinical trials, especially siRNA drugs that can target brain tissue for the treatment of brain diseases.
[0010] Recent studies have shown that spherical nucleic acids (SNA) can naturally enter various types of mammalian cells without the assistance of any targeting modification, lipids, or cationic delivery carriers, so spherical nucleic acid nanomaterials have been widely studied. SNA is a non-cationic nucleic acid nanostructure, generally composed of two plates, namely oligonucleotides and nanoparticle cores composed of inorganic metal materials or organic materials, and oligonucleotides are tightly and orderly arranged on the surface of nanocore particles. SNA actively crosses the cell membrane by binding to scavenger receptors and can enter cells autonomously, thereby facilitating its effective targeting of BBB and GBM cells with high expression of scavenger receptors. At the same time, the dense nucleic acid structure on the surface of SNA can resist the degradation of nucleases in serum and prolong the half-life of nucleic acid drugs in vivo. Therefore, SNA has been widely studied as a new strategy for nucleic acid drug delivery. Polymer materials such as PLGA, PNIPAM, and PMPC-PDPA have been used to develop new SNAs. These high molecular polymer materials can provide a hydrophobic core structure, which can self-assemble into SNAs with the peripheral hydrophilic nucleic acid structure in an aqueous environment. However, in the process of clinical trials and new drug applications, the requirements for clear drug composition and structure, long-term safety of materials, and the molecular weight dispersion and non-degradable characteristics of polymer materials have made the clinical transformation of currently developed polymer SNAs more difficult. Therefore, it is very meaningful to develop a simple, feasible, safe, efficient and easy-to-implement SNA nanomaterial.
[0011] Alpha-Lipoic acid (LA) is a small molecule naturally present in living organisms. LA is similar to a vitamin that can slow down aging and eliminate pathogenic free radicals, and has good biocompatibility. Its structure consists of a terminal carboxylic acid and a terminal disulfide bond, the latter of which is a saturated five-membered heterocyclic structure. This structure gives LA unique properties, making it both fat-soluble and water-soluble. After being absorbed through the intestines, it enters the cells and can pass through the body unimpeded to reach any cell site, providing comprehensive effectiveness to the human body. It is the only universal antioxidant that is both fat-soluble and water-soluble. LA can not only be used as a therapeutic drug, but is also widely used in the field of nano-drug delivery due to its good biocompatibility, carboxylic acid group reaction sites, and reduction sensitivity. Summary of the invention
[0012] In order to solve the problem of the difficulty of clinical transformation of high-molecular SNA prepared by existing high-molecular polymer materials, the present invention proposes siRNA micelles formed based on lipoic acid. The siRNA micelle structure of the present invention is safe and non-toxic, and can be used as an RNAi nanomedicine, wherein lipoic acid, as an endogenous substance, not only has good biocompatibility, but also has antioxidant and anti-inflammatory biological activities, and the nano-micelle particle size is about 45 nm.
[0013] The present invention adopts the following technical solutions: The siRNA micelle of the present invention is siRNA-LA n Spherical nucleic acid nanoparticles formed by self-assembly of diblock conjugates in an aqueous environment. Where n represents a positive integer.
[0014] In a further preferred embodiment, n=1-6.
[0015] The present invention uses natural small molecule LA as a basic unit and synthesizes lipoic acid material LA with a certain condensation degree through a series of condensation reactions. n -DBCO, and then covalently linked with azide-modified siRNA through click chemistry to form siRNA-LA with one end being hydrophilic and the other end being hydrophobic. n The diblock conjugate is then self-assembled in an aqueous environment through hydrophilic and hydrophobic forces to form spherical nucleic acid nanoparticles, namely siRNA micelles. The azide-modified siRNA is modified with an azide group at the 5' end of the sense strand of each siRNA.
[0016] The preparation of siRNA micelles specifically includes the following steps: Step 1: Using the natural small molecule LA as the basic unit, synthesize lipoic acid material LA with a certain degree of condensation through condensation reaction n -DBCO;LA n The synthesis of -DBCO is as follows: LA and DBCO compounds are directly obtained by condensation reaction. n -DBCO, or use Linker to condense LA and DBCO compounds to obtain LA n -DBCO, wherein the DBCO compound includes one of DBCO-NH2, DBCO-Acid, and DBCO-NHS, and the Linker includes 1,4,7,10-tetraazacyclododecane and Fmoc- L -A type of aspartic acid.
[0017] In a further scheme, LA-DBCO is directly synthesized by condensation of LA and DBCO-NH2; LA3-DBCO is obtained by condensation of 1,4,7,10-tetraazacyclododecane with four reaction sites and three LAs, and then condensation with DBCO-Acid; LA6-DBCO is obtained by covalently linking two LA3s through aspartic acid and then modifying them with DBCO.
[0018] Step 2: LA n -DBCO and azide-modified siRNAs were covalently linked by click chemistry to form siRNA-LA with one end being hydrophilic and the other end being hydrophobic. n Diblock conjugates; Specifically, LA n -DBCO solution and azide-modified siRNA solution were mixed, placed at 4°C overnight, and then melted at 20°C. This reaction process was repeated to prepare siRNA-LA. n Diblock conjugates.
[0019] Step 3: siRNA-LA n The diblock conjugates self-assemble in an aqueous environment to form spherical nucleic acid nanoparticles, i.e., siRNA micelles; Specifically, siRNA-LA n The mixed solution of diblock conjugates was added dropwise into DEPC water, and siRNA-LA n The diblock conjugates form spherical nucleic acid micelles through hydrophilic and hydrophobic interactions.
[0020] The present invention also provides the use of the siRNA micelles formed based on lipoic acid in preparing medicines for treating brain diseases.
[0021] In a further embodiment, the brain disease is glioma, and the siRNA in the siRNA micelle is a specific siRNA targeting PLK1 protein (PLK1 siRNA).
[0022] Furthermore, PLK1 siRNA includes: Sense strand (5′-3′) UGAAGAAGAUCACCCUCCUUAdTdT; Antisense strand (5′-3′) UAAGGAGGGUGAUCUUCUUCAdTdT.
[0023] In a further embodiment, the brain disease is Parkinson's disease, and the siRNA in the siRNA micelle is a specific siRNA targeting α-synuclein (SNCA siRNA).
[0024] Furthermore, SNCA siRNA includes: Sense strand (5′-3′) GGGUGUUCUCUA UGUAGGCTT; Antisense strand (5'-3') GCCUACAUAGAGAACACCCTT.
[0025] In addition, the present invention finds that the siRNA micelles formed based on lipoic acid have anti-oxidation and anti-inflammatory effects and can be used to prepare anti-oxidation drugs and anti-inflammatory drugs.
[0026] The beneficial effects of the present invention are: The siRNA micelles prepared based on LA in the present invention have stable physical and chemical properties, effectively protect siRNA from nuclease degradation, can be loaded with siRNA and delivered to brain tumor sites, and effectively treat brain gliomas by targeting PLK1 in the treatment of GBM. The siRNA micelles have the following advantages: (1) They do not rely on any delivery carrier or targeting molecule modification, and can efficiently cross the BBB and achieve targeting and effective endocytosis of GBM cells through scavenger receptor-mediated methods; (2) Based on LA, siRNA-LA is precisely chemically synthesized. n The conjugate has a clear structure, which avoids the approval difficulties caused by unclear structure during the clinical transformation of nanomedicines; (3) Compared with cationic carriers, negatively charged SNA causes less immune response, and LA, as an endogenous active substance, has excellent biosafety and anti-inflammatory and antioxidant medicinal value. These advantages provide very important reference significance for the clinical transformation and application of siRNA drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 : The synthetic route of LA-DBCO.
[0028] Figure 2 : H NMR spectrum of LA-DBCO.
[0029] Figure 3 :The synthetic route of LA3-DBCO.
[0030] Figure 4 : H NMR spectrum of LA3-DBCO.
[0031] Figure 5 :The synthetic route of LA6-DBCO.
[0032] Figure 6 : H NMR spectrum of LA6-DBCO.
[0033] Figure 7 :Schematic diagram of the preparation of nanomicelle siRNA-micelle.
[0034] Figure 8 :The loading of siRNA was investigated by agarose gel electrophoresis.
[0035] Fig. 9 : Particle size, potential and morphology of siRNA micelles. (a) Particle size of LA, LA3 and LA6 siRNA micelles dispersed in aqueous solution measured by DLS, (b) Potential values of siRNA and LA, LA3 and LA6 siRNA micelles dispersed in aqueous solution, (c) Morphology of LA6 siRNA micelles photographed by TEM.
[0036] Fig.10 :DLS was used to detect the particle size change of siRNA micelles. (a) siRNA micelles were dispersed in DEPC water to monitor the stability of their particle size and polydispersity coefficient, (b) siRNA micelles were dispersed in 10% FBS to monitor the stability of their particle size and polydispersity coefficient.
[0037] Fig.11 :U87MG cell uptake of siRNA micelles. (a) Flow cytometry analysis of siRNA micelles internalized by U87MG cells, (b) is the result of fluorescence quantitative analysis of flow cytometry result (a), (c) CLSM observation of U87MG tumor cells internalizing siRNA micelles.
[0038] Fig.12 :Flow cytometry was used to detect the endocytosis of cells co-incubated with poly I and siRNA micelles.
[0039] Fig.13 :In vitro antitumor effect of siPLK1 micelles. (a) Verification of gene silencing effect at the PLK1 mRNA level after loading with siPLK1, (b) Verification of gene silencing effect on PLK1 protein after loading with siPLK1, (c) Statistics of three WB results in (b), (d) Results of siPLK1 micelles inducing apoptosis of U87MG cells.
[0040] Fig.14 : Targeted enrichment ability of siRNA micelles in orthotopic U87MG-Luc tumor-bearing mice. (a) Distribution of siRNA micelles in vivo, (b) Quantification and statistics of fluorescence intensity in the mouse brain of (a), (c) Imaging of mouse brain tissue alone and comparison of in vivo tumor penetration effects of siRNA micelles and naked siRNA.
[0041] Fig.15: Tumor inhibition of U87MG Luc tumor-bearing nude mice by siPLK1-loaded siRNA micelles. (a) Treatment schematic diagram, (b) After the U87MG tumor model was established, drugs were injected via tail vein on days 6, 8, 10, and 12, and fluorescence imaging analysis was performed on days 6, 8, 10, 12, and 14, (c) Quantitative analysis of fluorescence imaging results, (d) Recording of weight changes of mice during treatment, (e) Recording of survival period of mice during treatment.
[0042] Fig.16 :Comparison of the uptake of siRNA micelles by PD-related cells. (a) Flow cytometry analysis of siRNA micelles in BV2 cells; (b) Flow cytometry analysis of siRNA micelles in SH-SY5Y cells.
[0043] Fig.17 :Anti-inflammatory experiment of siRNA micelles. (a) Schematic diagram of anti-inflammatory treatment of siRNA micelles; (b) mRNA expression levels related to anti-inflammatory factors of IL-1β (c) TNF-α (d) IL-6; (c) mRNA expression levels related to pro-inflammatory factors.
[0044] Fig.18 :siRNA micelles reduce the expression of ROS and NO caused by MPTP. (a) Flow cytometry analysis results of siRNA micelles reducing the expression of ROS caused by MPTP; (b) Confocal microscopy results of siRNA micelles reducing the expression of ROS caused by MPTP; (c) Flow cytometry analysis results of siRNA micelles reducing the expression of NO caused by MPTP.
[0045] Fig.19 :Biological distribution of siRNA micelles. (a) Fluorescence imaging results of mouse brain 2 h after siRNA micelle and siRNA injection; (b) In vitro imaging results of brain 2 h after siRNA micelle and siRNA injection.
[0046] Fig. 20 : Treatment experiments of PD mice. (a) Schematic diagram of treatment of PD mice; (b) Results of the U-turn test of PD mice; (c) Results of the climbing pole test of PD mice; (d) Results of the rotarod test of PD mice.
[0047] Fig.21 : Results of the open field experiment of PD mice. (a) The trajectory of the mice in the open field; (b) The analysis results of the total distance traveled by the mice; (c) The analysis results of the speed of the mice in the open field; (d) The analysis results of the total rest time of the mice in the open field.
[0048] Fig. 22:H&E staining results of tissues and organs and analysis of blood biochemistry, blood routine and immune factor levels. (a) H&E staining results of brain tumors or organs, (b) mRNA levels of proinflammatory factors, (c) blood routine and blood biochemistry analysis results. DETAILED DESCRIPTION
[0049] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution in the embodiment of the present invention will be clearly described below in conjunction with the drawings in the embodiment of the present invention. Obviously, the described embodiment is a part of the embodiment of the present invention, not all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0050] The azide-modified siRNA used in the examples was purchased from Suzhou Beixin Biotechnology. The azide-modified siRNA was modified with an azide group at the 5' end of the sense strand of each siRNA.
[0051] The siRNA sequences involved in the embodiments are: Scramble siRNA: Sense strand (5′-3′): UUCUCCGAACGUGUCACGUdTdT; Antisense strand (5′-3′): ACGUGACACGUUCGGAGAAdTdT; PLK1 siRNA: Sense strand (5′-3′): UGAAGAAGAUCACCCUCCUUAdTdT; Antisense strand (5'-3'): UAAGGAGGGUGAUCUUCUUCAdTdT.
[0052] SNCA siRNA: Sense strand (5′-3′): GGGUGUUCUCUAUGUAGGCTT; Antisense strand (5'-3'): GCCUACAUAGAGAACACCCTT.
[0053] 1. Spherical nucleic acid siRNA-LA n The synthetic route: 1. Synthesis of LA-DBCO Weigh lipoic acid (LA, 0.20 g, 0.97 mmol) into a 50 mL round-bottom flask and add appropriate amount of N,N - dimethylformamide (DMF) until the raw materials are completely dissolved, add benzotriazole- N,N,N',N' -Tetramethyluronium hexafluorophosphate (HBTU, 0.37 g, 0.97 mmol) and N,N -Diisopropylethylamine (DIPEA, 0.37 g, 2.91 mmol), stir at room temperature for 5 min, add diphenylcyclooctynamine (DBCO-NH2, 0.22 g, 0.81 mmol). Stir at room temperature for 6 h. After the reaction of the raw materials is complete by thin-layer chromatography (TLC), extract with appropriate amount of ethyl acetate (EA) and saturated sodium bicarbonate (NaHCO3), collect the organic phase, wash with saturated sodium chloride (NaCl), collect the organic phase again, dry with anhydrous sodium sulfate (Na2SO4), concentrate in vacuo, and purify by column chromatography to obtain compound 1 (LA-DBCO, 0.30 g, 66.7%) as a light yellow oil. The synthetic route of LA-DBCO is as follows Figure 1 The H NMR spectrum of LA-DBCO is shown in Figure 2 shown.
[0054] 2. Synthesis of LA3-DBCO (1) First weigh 1,4,7,10-tetraazacyclododecane (2.78 g, 16.18 mmol) into a 200 mL single-necked round-bottom flask, add an appropriate amount of DMF until the raw material is completely dissolved, then take another 200 mL round-bottom flask, add LA (10 g, 48.54 mmol), add an appropriate amount of DMF until LA is completely dissolved, and add O -Benzotriazole- N,N,N',N' -Tetramethyluronium tetrafluoroborate (TBTU, 15.58 g, 48.54 mmol) and DIPEA (12.54 g, 97.10 mmol), stirred at room temperature for 5 min, slowly added dropwise to a DMF solution containing 1,4,7,10-tetraazacyclododecane, stirred at room temperature for 6 h. Extracted with appropriate amount of EA and saturated NaHCO3, collected the organic phase, washed with NaCl, collected the organic phase, dried over anhydrous Na2SO4, concentrated in vacuo, and purified by column chromatography to obtain compound 2 (7.80 g, 65.4%) as a yellow oil.
[0055] (2) Weigh diphenylcyclooctyne-carboxylic acid (DBCO-acid, 80 mg, 0.26 mmol) and dissolve it in dichloromethane (DCM), add 1, 3-dicyclohexylcarbodiimide (DCC, 53.63 mg, 0.26 mmol), then add compound 2 (41.50 mg, 0.26 mmol), then add 4-dimethylaminopyridine (DMAP, 3.67 mg, 0.03 mmol) and stir at room temperature for 12 h. Monitor the reaction progress by TLC, extract with appropriate amount of DCM and saturated NaHCO3, collect the organic phase, wash with saturated NaCl, collect the organic phase, dry with anhydrous Na2SO4, concentrate in vacuo, and purify by column chromatography to obtain compound 3 (LA3-DBCO, 138 mg, 52.1%) as a yellow oil. The synthetic route of LA3-DBCO is as follows: Figure 3 The H NMR spectrum of LA3-DBCO is shown in Figure 4 shown.
[0056] 3. Synthesis of LA6-DBCO (1) Weigh Fmoc- L -Aspartic acid (1.21 g, 3.39 mmol) was placed in a 50 mL round-bottom flask and an appropriate amount of DCM was added to the Fmoc- L -Aspartic acid was completely dissolved, DCC (1.4 g, 6.79 mmol) and DMAP (85 mg, 0.7 mmol) were added and stirred at room temperature for 5 min, and compound 2 (2.50 g, 3.39 mmol) was added and stirred at room temperature. The reaction of compound 2 was monitored by TLC until the reaction was complete, and then an equal amount of compound 2 (2.50 g, 3.39 mmol) was added and stirred overnight. Extraction was performed with an appropriate amount of DCM and saturated NaHCO3, the organic phase was collected, and then washed with saturated NaCl, the organic phase was collected, dried over anhydrous Na2SO4, concentrated in vacuo, and purified by column chromatography to obtain compound 4 (1.50 g, 24.7%) as a yellow solid.
[0057] (2) Compound 4 (200 mg, 0.11 mmol) was weighed into a 50 mL round-bottom flask, DMF (2 mL) was added, and morpholine (0.50 mL) was slowly added dropwise. The mixture was stirred at room temperature for 30 min, extracted with appropriate amount of EA and saturated NaHCO3, the organic phase was collected, and then washed with saturated NaCl. The organic phase was collected again, dried over anhydrous Na2SO4, concentrated in vacuo, and purified by column chromatography to obtain the deprotected product (83.50 mg, 48.3%) as a yellow solid.
[0058] (3) The product of the previous step (83.50 mg, 0.05 mmol) was weighed into a 50 mL round-bottom flask and dissolved in an appropriate amount of DCM. Diphenylcyclooctyne active ester (DBCO-NHS, 14 mg, 0.04 mmol) was weighed and added to the reaction system. The mixture was stirred at room temperature for 8 h under N2 environment. The mixture was extracted with an appropriate amount of DCM and saturated NaHCO3, the organic phase was collected, and then washed with saturated NaCl. The organic phase was collected again, dried over anhydrous Na2SO4, concentrated in vacuo, and purified by column chromatography to obtain compound 5: LA6-DBCO (50 mg, 51.55%) as a yellow oil. The synthetic route of LA6-DBCO is as follows: Figure 5 The H NMR spectrum of LA6-DBCO is shown in Figure 6 shown.
[0059] 4. Synthesis of Nanomicelle siRNA-LA n siRNA-LA n The synthesis of the conjugate is achieved by chemical covalent bonding generated by click chemistry reaction between alkyne and azide groups. Figure 7 As shown. Taking the synthesis of siRNA-LA6 conjugate as an example, weigh LA6-DBCO (1.666 mg), dissolve it in dimethyl sulfoxide (DMSO, 1 mL) to prepare a solution with a concentration of 1.666 mg / mL; take azide-modified siRNA (0.5 mg) and dissolve it in DMSO (400 μL) to prepare a solution of 1.2 mg / mL, and vortex thoroughly to completely dissolve the azide-modified siRNA. Take 100 μL (166.6 μg, 92.5 nmol) of LA6-DBCO solution with a concentration of 1.666 mg / mL, and take another 100 μL (125 μg, 9.26 nmol) of azide-modified siRNA solution with a concentration of 1.2 mg / mL, mix them thoroughly, place them at 4°C overnight, and then place the sample at 20°C to melt. Repeat this reaction process 3 times to prepare siRNA-LA n Conjugate.
[0060] siRNA and LA n After the -DBCO coupling, the siRNA micelles were prepared. n The mixed solution of the conjugate was added dropwise into DEPC (2 mL) water and stirred at a constant speed for 2 h. nThe conjugate forms spherical nucleic acid micelles through hydrophilic and hydrophobic interactions, and then is transferred to a 3.5 kDa dialysis bag and dialyzed in an aqueous solution for 4 h to remove DMSO from the reaction system. After dialysis, the sample is collected in a centrifuge tube and centrifuged (10,000 rpm, 3 min) to collect the supernatant, thereby removing the residual LA in the reaction system. n -DBCO, the purified siRNA micelle solution can be obtained.
[0061] 2. Characterization and exploration of nanomicelles 1. Nanomicelle siRNA-LA n Gel electrophoresis experiments Nucleic acid gel electrophoresis assay to detect whether siRNA binds to LA n -DBCO coupling and self-assembled into siRNA micelles in water environment.
[0062] The results of nucleic acid gel electrophoresis experiments are as follows Figure 8 As shown, siRNA-LA n Compared with naked siRNA, the siRNA micelles formed by the diblock conjugates showed a slower migration speed on the nucleic acid gel, which is consistent with the gel electrophoresis results that spherical nucleic acids migrate more slowly than free siRNA in electrophoresis. n The larger the molecular weight of the -DBCO compound, the slower the migration rate. This explains the n -DBCO was successfully coupled by covalent bonding and siRNA micelles were prepared. There was no free siRNA band in the reaction system of siRNA micelles, indicating that all siRNA was coupled to LA n -DBCO, the reaction efficiency of azide-modified siRNA is nearly 100%.
[0063] 2. Characterization of siRNA micelle particle size, potential and morphology In an aqueous environment, one end is hydrophilic (siRNA) and the other end is hydrophobic (LA n ) siRNA-LA n The diblock complexes self-assembled into spherical nucleic acid micelles under the hydrophilic and hydrophobic forces. The particle sizes of the three siRNA micelles LA, LA3 and LA6 were measured by DLS to be 135.3 nm, 119.0 nm and 43.3 nm, respectively, and the PDIs were 0.333, 0.231 and 0.210. Fig. 9 a. siRNA-LA n The overall particle size is uniform and has good dispersibility. The particle size of siRNA micelles decreases as the number of LA on the material increases, and the dispersion coefficient also decreases. This may be due to the increase in the number of LA and the increase in the dispersion coefficient of siRNA-LA. nThe hydrophobic interaction between the LA ends of the diblock complex is enhanced, and the inner core with stronger hydrophobic interaction results in a smaller particle size of the siRNA micelles.
[0064] like Fig. 9 As shown in b, the Zeta measurement results show that free siRNA and three siRNA micelles are all negatively charged. Due to the high density of nucleic acids on the surface of siRNA micelles, the charge is more negative.
[0065] like Fig. 9 As shown in c, the TEM image shows the clear morphology of the siRNA micelles, which are regular spherical in shape and have uniform particle size, which is basically consistent with the particle size measured by DLS, and also indicates the successful synthesis of the siRNA micelles.
[0066] 3. Stability experiment of nanomicelles In order to investigate whether siRNA micelles are stable during long-term storage, the prepared freshly dispersed siRNA micelles in water were stored at 4°C. 100 μL of siRNA micelle solution was taken out at 0, 1, 2, 3, 4, 5, 6 and 7 days after storage, and the particle size and PDI of siRNA micelles at each time point were detected by DLS. In order to investigate the stability of siRNA micelles under in vitro conditions, siRNA micelles were dispersed in PBS buffer containing 10% FBS and placed at 37°C. Then, siRNA micelle solution (100 μL) was taken out at 0, 1, 2, 3, 4, 5, 6 and 7 days, and the particle size and PDI of siRNA micelles were detected by DLS. When siRNA micelles were dispersed in DEPC water and stored at 4°C, their particle size hardly changed within a week ( Fig.10 This demonstrates the ease of storage of our siRNA micelles.
[0067] In addition, the particle size of siRNA micelles was not significantly changed under physiological conditions (37°C, 10% FBS). The siRNA micelles were dispersed in 1×PBS buffer containing 10% FBS and incubated at 37°C. The particle size and PDI of siRNA micelles were monitored by DLS for 7 consecutive days. During this period, the particle size of siRNA micelles remained stable ( Fig.10 (b). On the 7th day, the particle size of the siRNA micelles in FBS became larger, which is presumably due to the interaction with the proteins in the serum, which is also reflected in the nucleic acid gel electrophoresis results. The enhanced stability of the siRNA micelles may enable it to maintain its structure for a longer period of time under physiological conditions, thereby possibly extending the blood circulation time during the GBM treatment in vivo and improving the treatment effect.
[0068] 3. Nanomicelle Cell Behavior Experiment 1. Flow cytometry to detect the internalization of nanoparticles by cells In order to explore the cellular internalization of siRNA micelles, we selected the LA6 siRNA micelles with the smallest particle size for subsequent cellular level effect verification based on the previous characterization of three siRNA micelles based on LA, LA3 and LA6. Fig.11 As shown in a, compared with free Cy5-siRNA, U87 MG cells incubated with Cy5-siRNA micelles have stronger fluorescence signals. The flow cytometry statistical results are shown in Fig.11 b, Compared with free Cy5-siRNA, the Cy5 fluorescence signal of Cy5-siRNA micelle group increased by about 4.5 times. Fig.11 c, The accumulation of siRNA micelles in U87MG cells captured by CLSM is significantly stronger than that of free siRNA, which further intuitively confirms the cell uptake trend verified by flow cytometry. And by locating the nucleus with DAPI dye and the cytoskeleton with FITC-labeled phalloidin, it can be seen that most of the siRNA micelles accumulate in the cytoplasm of U87MG. Free siRNA has a very limited cell uptake ability, and siRNA micelles show strong cell endocytosis, because siRNA micelles can be taken up by cells through the scavenger receptor-mediated endocytosis pathway.
[0069] 2. Flow cytometry assay for cell uptake inhibition In order to verify that the pathway of siRNA micelles, which are spherical nucleic acid nanoparticles, entering cells is mediated by scavenger receptors, we used Poly I (polyinosinic acid, a scavenger receptor inhibitor) and Cy5-labeled siRNA micelles to co-incubate with U87MG cells, and set up siRNA micelles without scavenger receptor inhibitors and free Cy5-labeled siRNA groups as controls. From the flow cytometry results ( Fig.12 ), the fluorescence intensity of siRNA micelles was significantly higher than that of free siRNA, and the endocytosis effect of the group with scavenger receptor inhibitors decreased sharply, and with the increase of inhibitor concentration, the effect of gradient decrease was shown. This proves that the mechanism of spherical nucleic acid micelles being taken up by cells is scavenger receptor-mediated endocytosis, and scavenger receptors play a very important role in the cellular uptake of siRNA micelles.
[0070] 3. In vitro anti-tumor experiment of siRNA micelles Polo-like kinase 1 (PLK1) is a serine / threonine protein kinase, an important protein associated with cell mitosis, and is essential for the rapid proliferation of tumor cells. It has been reported that PLK1 protein plays a key role in the malignant transformation of brain glioma. Therefore, based on the previous characterization of siRNA micelle nanoparticles and the evaluation of good cell uptake ability, we selected specific siRNA (siPLK1) micelles targeting PLK1 protein to treat U87MG cancer cells. The gene silencing effect of siRNA micelles was detected by real-time fluorescence quantitative PCR. The expression level of PLK1 mRNA under the action of siPLK1 micelles was reduced by approximately 27.98% (200 nM) and 37.91% (400 nM), respectively. However, free siPLK1 and non-functional siScr (ScramblesiRNA) micelles showed negligible changes in PLK1 mRNA expression levels, such as Fig.13 As shown in a.
[0071] siPLK1 micelles showed good gene silencing effect at the PLK1 mRNA level. We then evaluated the specific silencing effect of siRNA micelles at the PLK1 protein expression level. The results are as follows: Fig.13 As shown in b, compared with the PBS, free siPLK1 and siScr micelle groups, the PLK1 protein in the siPLK1 micelle treatment group showed a significantly lower expression level, as shown in Fig.13 c, Quantitative analysis of the data using Image J software revealed that the PLK1 protein expression levels in U87MG tumor cells under the action of siPLK1 micelles were reduced by approximately 27.98% (200 nM) and 37.91% (400 nM), respectively. Free siPLK1 and non-functional siScr micelles showed negligible changes in PLK1 protein expression levels. WB experiments further verified that the siPLK1 micelles we prepared had a good gene silencing effect.
[0072] The ability of siRNA micelles to induce apoptosis in cancer cells was then evaluated. Fig.13 As shown in Figure d, siPLK1 micelles induced significant early and late apoptosis in U87MG cells (23.34%). Compared with PBS, siScr micelles or free siPLK1 had almost no apoptotic effect, and the proportion of live cells was above 90%. In summary, these results show that our cationic-free siRNA micelles can rely on efficient cell endocytosis to deliver functional siRNA to achieve specific silencing of cancer cell-related genes and induce cell apoptosis, providing great potential for in vivo anti-tumor research.
[0073] 4. Nanomicelle Animal Behavior Experiment 1. Animal model construction All animal handling protocols and experiments in this study were approved by the Medical and Scientific Research Ethics Committee of Henan University School of Medicine (China) (HUSOM-2023-164).
[0074] The specific steps of constructing the U87MG tumor-bearing mouse model were as follows: U87MG-Luc cell pellets were collected, and Balb / c mice were anesthetized with 1% pentobarbital at a dose of 50 mg / kg intraperitoneally. The skulls of the mice were drilled with a skull drill, and 1×10 5 The cells were injected into the mouse brain in a volume of 5 μL. After tumor cell inoculation, the burr hole was sealed with bone wax, and then the wound on the mouse head was sealed with tissue glue. About six days after inoculation, the mice were imaged with bioluminescence using a live small animal imager to detect whether the tumor was successfully loaded.
[0075] 2. In vivo fluorescence imaging of siRNA micelles In order to evaluate the in vivo biodistribution of siRNA micelles, we first established a U87MG tumor-bearing mouse model, and used a small animal imager to detect the tumor size of the U87MG-Luc orthotopic tumor model mice. Mice with consistent tumor size and good growth status were selected for in vivo biodistribution experiments. The specific steps were as follows: Cy5-labeled siRNA micelles and free siRNA (n = 3 (3 replicates per group), 1 mg Cy5-siRNA equiv. / kg) were injected through the tail vein, and in vivo imaging and analysis were performed using the fluorescence imaging system of the small animal in vivo imager at 0.5, 1, 2, 4, 6, and 12 h after the injection. The results are shown in Figure 2. Fig.14 As shown in Figures a and 14b, free siRNA showed only negligible fluorescence intensity in the mouse brain organs, while siRNA micelles accumulated more in the brain. This indicates that free siRNA has difficulty crossing the BBB to reach the brain in vivo, while siRNA micelles can cross the BBB through the scavenger receptor-mediated transcytosis pathway and accumulate in the brain to a certain extent.
[0076] To evaluate the in vivo tumor penetration ability of siRNA micelles, Cy5-labeled siRNA micelles and free siRNA (n = 3 (3 replicates per group), 1 mg Cy5-siRNA equiv. / kg) were injected via tail vein, and then tumor-bearing mice were euthanized 1 h later, and intact tumor-bearing brain tissues were collected for imaging. The results are shown in Fig.14 As shown in c, siRNA micelles accumulated more in brain tissue and the fluorescence signal of Cy5 was stronger.
[0077] Then fix it with 4% paraformaldehyde overnight, dehydrate it with sucrose, embed it with tissue embedding agent (OTC), and slowly freeze it in liquid nitrogen. After the tissue is embedded, the frozen section experiment can be carried out, and brain tumor sections are obtained using a low-temperature freezing microtome. Then the tissue sections are subjected to immunofluorescence staining analysis, the steps are: fix it with 4°C pre-cooled acetone for 15 minutes, after fixation, wash it 3 times with 0.3% Triton X-100, stain the cell nuclei of the tissue sections with DAPI for 10 minutes, then wash it 3 times with 0.3% Triton X-100 and scan it with CLSM. The results are as follows Fig.15 As shown in Figure c, siRNA micelles show stronger fluorescence accumulation in tissue sections, and siRNA micelles are selectively accumulated in tumor tissues, while the accumulation in normal tissues is negligible. This further proves that the siRNA micelles we prepared can not only effectively cross the blood-brain barrier and accumulate in the brain, but also have the effect of targeting tumor tissues. These results further prove that siRNA micelles have efficient tumor targeting ability in vivo.
[0078] 3. siRNA micelle multi-gene inhibition in situ model mouse treatment experiment like Fig.15 As shown in a and 15b, the tumor size of BALB / c nude mice in the U87MG-Luc orthotopic tumor model was detected using a small animal imager. Tumor-bearing mice with consistent tumor size and good growth status were selected and randomly divided into three groups (n = 10, i.e., 10 replicates in each group). 200 μL PBS, siScr micelles, and siPLK1 micelles (2 mg siRNA equiv. / kg) were administered by tail vein injection once every 2 days. The mice were weighed before each administration and the relative weight of the mice was calculated. The tumor growth of the treated mice was monitored using a small animal imager and the relative fluorescence intensity was quantified. On the 14th day of treatment, two mice in each group were randomly killed, and the remaining mice were used to observe the survival cycle.
[0079] The tumor tissue of one of the mice was collected, ground with tissue lysis buffer, and the protein-containing supernatant was collected by centrifugation. The concentration of the sample was detected by BCA protein quantification kit, and the expression level of PLK1 protein in mouse tumor tissue was detected by WB experiment. The main organs such as heart, liver, spleen, lung, kidney and brain of another mouse that was killed were collected, fixed with 4% paraformaldehyde overnight, rinsed with running water for 4 hours, and dehydrated with an automatic tissue dehydration instrument, and then embedded and sliced. H&E evaluated the in vivo safety of siRNA micelles; Cleaved Caspase 3 (CC3) immunofluorescence was used to detect the expression level of apoptosis-related proteins (CC3); Ki67 immunofluorescence was used to detect the proliferation intensity of tumor cells to evaluate the tumor inhibitory effect of siRNA micelles; TUNEL experiment was used to detect the apoptosis of tumor cells to evaluate the effect of siRNA micelles in inducing tumor cell apoptosis.
[0080] The results showed that compared with the PBS and siScr micelle groups, the bioluminescence intensity of mouse tumors in the siPLK1 micelle treatment group was significantly weaker, indicating that siPLK1 micelles can pass through the blood-brain barrier through the scavenger receptor-mediated endocytosis pathway and target tumor tissues, achieving good tumor accumulation and thus exerting an inhibitory effect on the growth of U87MG tumor tissues.
[0081] After the treatment, the bioluminescence intensity of the tumor in each imaging was quantified and normalized. It was found that siPLK1 micelles showed a strong inhibitory effect on the growth of in situ U87MG tumors in mice. On the contrary, the tumors of mice in the PBS group and siScr micelle group showed an almost continuous growth trend. The bioluminescence signal intensity of the tumor in the PBS group was 8 times that of the siPLK1 micelle group, while the bioluminescence signal intensity of the tumor in the siScr micelle group was 3.5 times that of the siPLK1 micelle group, and the bioluminescence signal intensity of the tumor in the PBS group was 2.5 times that of the siScr micelle group. Fig.15 As shown in Figure c, this further verifies the significant inhibitory effect of siPLK1 micelles on the growth of U87MG-Luc brain glial tumor cells in the mouse brain, and also verifies the certain therapeutic effect of siScr micelles. During the treatment period of siPLK1 micelles, the weight of mice in the siPLK1 group hardly changed, as shown in Figure d. Fig.15 As shown in Figure d, except for a slight weight gain in the early stage of treatment, the mice in the PBS and siScr micelle groups experienced a certain weight loss process. In contrast, the weight loss rate of the mice in the siScr micelle treatment group was slower than that in the PBS group. This may be because the rapid growth of the tumor in the mouse brain destroyed the brain function, resulting in the restriction of the normal physiological activities of the mice, thus causing weight loss. More importantly, at the end of the treatment, Fig.15As shown in Figure e, survival curve analysis showed that the median survival time of mice in the siPLK1 micelle treatment group was 31 days, which was significantly longer than that of tumor-bearing mice in the siScr micelle (23 days) and PBS (20 days) treatment groups. The siPLK1 micelle treatment group had the highest survival rate, and siPLK1 micelle treatment extended the lifespan of tumor-bearing mice.
[0082] It should be noted that siScr micelles also have a certain inhibitory effect on tumor growth compared with PBS. Whether in imaging, survival cycle, or mouse weight tests, siScr micelles have a certain therapeutic effect. This result is surprising, which may be related to the properties of LA. The specific mechanism is still under study. We hope to develop a multifunctional material that can not only deliver siRNA as a carrier, but also play a pharmacological role through exploration.
[0083] 5. Application of Nanomicelles in Parkinson's Disease Model 1. Cellular Uptake Experiment siRNA micelles and free siRNA both carry negative charges. Compared with free siRNA, siRNA micelles can enter cells through scavenger receptor-mediated endocytosis. In order to explore the cellular uptake ability of siRNA micelles, Cy5-siRNA and Cy5-siRNA micelles were co-incubated with SH-SY5Y and BV2 cells for 10 h, and the cell uptake was quantitatively detected using a flow cytometer. The results are shown in Figure 2. Fig.16 As shown in a, compared with free siRNA, siRNA micelles treated BV2 cells showed higher fluorescence intensity, with a fluorescence difference of 3.4 times. Fig.16 As shown in b, SH-SY5Y cells treated with siRNA micelles showed higher fluorescence intensity compared with free siRNA, with a fluorescence difference of 6.0 times.
[0084] 2. Evaluation of the anti-inflammatory effect of micelles Activation of microglia plays a crucial role in neurodegenerative diseases. Fig.17 As shown in a, activated microglia present a classic M1 phenotype, which is associated with proinflammatory mediators, including IL-6, TNF-α, and IL-1β, while selectively activated M2 microglia are associated with specific proteins, such as Arg-1 and Ym-1. Lipoic acid has anti-inflammatory effects. In order to detect whether this lipoic acid-based siRNA micelle also has anti-inflammatory effects, real-time fluorescence quantitative PCR was used to detect the expression level of inflammatory signals in LPS-induced microglia. After pretreatment with siRNA micelles (0, 200, 400 nM) for 6 h, LPS was used to induce inflammation for 24 h. The results are shown in Fig.17b, 17c, and 17d show that the mRNA expression levels of TNF-α, IL-6, and IL-1β in BV2 cells treated with LPS alone were increased compared with those in cells without any treatment, e.g. Fig.17 As shown in Figure e, the mRNA expression levels of Arg-1 and Ym-1 proteins associated with the M2 phenotype decreased slightly. Compared with BV2 cells treated with LPS alone, the mRNA expression levels of inflammatory factors such as IL-6, TNF-α, and IL-1β in cells pretreated with siRNA micelles were significantly reduced, approaching the expression levels of the PBS group, and showed concentration dependence. At the same time, the mRNA expression levels of anti-inflammatory factors such as Arg-1 and Ym-1 increased. This proves that the lipoic acid-based siRNA micelles we designed can significantly reduce the inflammatory level of LPS-induced microglia at a lower concentration.
[0085] 3. Evaluation of the Antioxidant Effect of Micelles In neurodegenerative diseases, activated microglia not only produce inflammatory factors such as TNF-α, IL-6 and IL-1β, but also produce other cytotoxic molecules (such as ROS, NO, etc.) to cause neuronal damage. Lipoic acid has been shown to have antioxidant activity. In order to verify that this lipoic acid-based siRNA micelle also has antioxidant activity and can scavenge reactive oxygen species, the DCFH-DA probe was used to study the ability of siRNA micelles to reduce MPTP-induced ROS. The results of flow cytometry analysis are shown in Figure 2. Fig.18 As shown in a, the ROS level of BV2 cells treated with MPTP for 12 h increased by 3.32 times compared with untreated cells, while pretreatment with siRNA micelles significantly reduced the production of ROS induced by MPTP. Fig.18 As shown in b, in BV2 cells induced by MPTP, the green ROS fluorescence signal was significantly enhanced, while in BV2 cells pretreated with siRNA micelles, the fluorescence signal was significantly weakened, which was basically consistent with the fluorescence intensity of normal BV2 cells. These results further illustrate that siRNA micelles can effectively reduce the level of ROS induced by MPTP, and this lipoic acid-based siRNA micelle also has the ability to scavenge reactive oxygen species.
[0086] In addition to ROS, the overproduction of NO in activated glial cells is also believed to play a crucial role in neurodegenerative diseases. In order to prove that siRNA micelles can effectively scavenge NO, DAF-FM DA (NO probe) was used to detect the ability of siRNA micelles to reduce MPTP-induced NO. The results are shown in Fig.18As shown in Figure c, the NO level in cells treated with MPTP increased by 5.42 times, and in BV2 cells pretreated with siRNA micelles, the NO expression level decreased significantly, which was basically the same as the NO level in normal BV2 cells. These results indicate that siRNA micelles can effectively eliminate MPTP-induced NO.
[0087] 4. Evaluation of the brain targeting ability of micelles in PD models In order to further study the accumulation effect of siRNA micelles in the brain, 6-month-old PD mice were used for in vivo tracking imaging. The PD mice were bred by A53T transgenic C57 mice (male mice) and normal C57 mice (female mice) and obtained by genotyping. A53T transgenic C57 mice were purchased from Beijing Huafukang Biotechnology Co., Ltd., and normal C57 mice were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd. All animal experiments were performed in accordance with the Animal Care and Use Regulations of Henan University.
[0088] Specifically, Cy5-siRNA micelles and Cy5-siRNA were injected into mice via the tail vein, and in vivo fluorescence imaging was performed at specified time points. Fig.19 Figure a shows that 2 hours after tail vein injection, the brain of mice injected with siRNA micelles had stronger fluorescence intensity than that of free siRNA, indicating that this type of siRNA micelles has a strong BBB penetration ability. Subsequently, 2 hours after tail vein injection, the mice were euthanized and the organs were imaged in vitro. The results are shown in Figure 2. Fig.19 b shows that the brains of mice injected with siRNA micelles showed higher fluorescence intensity compared with those injected with free siRNA, further proving that this siRNA micelle has stronger BBB penetration ability.
[0089] 5. α-syn plays a crucial role in the pathogenesis of PD The pathological characteristics of PD are mainly the loss of dopamine neurons and the abnormal accumulation of α-synuclein (α-syn) in the substantia nigra (SN). α-syn encoded by the SNCA gene plays a vital role in the disease progression of PD. Specific siRNA (siSNCA) targeting α-syn was used as a therapeutic siRNA to treat mice with PD. PD mice were randomly divided into 3 groups on average, with 7 mice in each group. Fig. 20 As shown in a, PBS, siScr micelles and siSNCA micelles (siRNA concentration was 2 mg / kg) were injected every three days for a total of 10 times. Pole climbing test, rotarod test and open field test were performed one week after the end of treatment.
[0090] The head-turning test is to compare the movement ability of mice by recording the time required for mice to adjust from head-up to head-down at the top of the climbing pole. Fig. 20 As shown in Figure b, in the U-turn experiment, the U-turn time of mice treated with siSNCA micelles was significantly shorter than that of the PBS group, which was basically the same as that of the WT group. In addition, the U-turn time of mice treated with siScr micelles was also significantly shorter than that of the PBS group, but longer than that of the siSNCA micelle group, which may be due to the anti-inflammatory effect of lipoic acid in siScr micelles.
[0091] The pole climbing test is a method to detect motor dysfunction in mice. It mainly compares the motor coordination of mice by comparing the time required for mice to climb from the top to the bottom of the pole. Fig. 20 As shown in c, compared with the PD mice in the PBS group and the siScr micelle treatment group, the time required for PD mice treated with siSNCA micelles to climb the pole was significantly shortened, and the time required was close to that of the WT group mice.
[0092] like Fig. 20 As shown in (d), compared with the mice in the PBS group and the siScr group, the mice in the siSNCA group stayed on the accelerator significantly longer, which was basically the same as that of the WT mice.
[0093] The above results show that siSNCA micelles can effectively improve the motor coordination and balance ability of mice, improve the motor dysfunction of mice, and have a good effect on the treatment of PD mice. In addition, the designed siRNA micelles based on lipoic acid structure themselves have a certain effect in improving the behavioral characteristics of mice.
[0094] The open field test is a classic method for evaluating the autonomous movement ability of mice. It mainly compares the differences in the movement ability and activity ability of mice by counting the total distance, speed and static time of mice in the open field and observing the movement trajectory of mice in the open field. The autonomous movement ability of mice was evaluated by the open field test. The results are as follows Fig.21 As shown in a, compared with the WT mice, the PD mice had a smaller range of movement in the middle area, while the mice treated with siSNCA micelles had a similar range of movement in the central area to that of the WT mice. Fig.21As shown in Figures 21b, 21c and 21d, the autonomous movement ability of mice treated with siRNA micelles was improved, especially the mice in the siSNCA group, which had a longer range of motion in the open field, a faster movement speed and less rest time in the quantitative analysis. The autonomous movement ability of this group of mice was better than that of other groups, which was basically consistent with that of the WT group of mice. The results of the open field experiment show that siSNCA micelles can effectively improve the autonomous movement ability of PD mice, and further show that siSNCA micelles can effectively delay the progression of PD.
[0095] VI. Safety analysis of physiological and biochemical indicators of siRNA micelles in vivo In order to further evaluate the biosafety of siRNA micelles, in addition to H&E staining analysis of tissue sections of major organs of mice, we can also detect blood routine parameters and characteristic substances in serum from the whole blood of mice to fully understand the effects of siRNA micelles on the physiological functions of mice.
[0096] (1) H&E staining analysis was performed on the important tissue and organ sections of the mouse. The results are as follows: Fig. 22 As shown in a, after treatment with siScr micelles and siPLK1 micelle nanoparticles, there was no significant difference in the results of tissue organ sections stained with H&E compared with the PBS control group, indicating that siPLK1 micelle nanoparticles did not produce toxic side effects in mice and had good biosafety.
[0097] (2) Routine blood test: By testing platelets (PLT), red blood cells (RBC), white blood cells (WBC) and other parameters, we can understand the effect of siRNA micelles on the blood system of mice. Experimental data showed that the blood cell parameters of the experimental group and the control group were basically the same, indicating that siRNA micelles did not have obvious toxic effects on the blood system of mice.
[0098] (3) Blood biochemical examination: By analyzing the characteristic substances in the serum, such as serum alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum albumin (ALB), urea (UREA), creatinine (CREA), uric acid (UA), etc., we can understand the effect of siRNA micelles on the function of mouse liver, kidney and other organs. Experimental data such as Fig. 22 c shows that the levels of serum characteristic substances in the experimental group and the control group were basically consistent, indicating that the siRNA micelles did not produce obvious toxic effects on the liver, kidneys and other organs of mice.
[0099] (4) Fluorescence quantitative PCR technology for immune factors: In order to further detect the inflammatory response of the liver and kidney caused by siRNA micelles, we used fluorescence quantitative PCR technology to evaluate the gene expression of pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β) in the liver and kidney organs. The experimental data are as follows Fig. 22 b shows that within two weeks after injection, the expression levels of various genes in the liver and kidney of the PBS and siRNA-micelle treatment groups remained at basically the same level, indicating that the nanoparticles have little effect on liver and kidney function and show good biocompatibility.
[0100] In summary, these experimental results strongly demonstrate that siRNA micelles have high biosafety in mice and do not cause obvious toxic side effects or functional damage to their major organs. These data further support the potential of siRNA micelles as a safe and effective drug delivery system for the treatment of brain glioma and other diseases.
[0101] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A siRNA micelle formed based on lipoic acid, characterized in that: The siRNA micelle is siRNA-LA n Spherical nucleic acid nanoparticles formed by self-assembly of diblock conjugates in an aqueous environment; wherein n represents a positive integer.
2. The siRNA micelle formed based on lipoic acid according to claim 1, characterized in that n=1~6。 3. The method for preparing siRNA micelles based on lipoic acid formation according to claim 1 or 2, characterized in that: Using lipoic acid as the basic unit, LA is synthesized through condensation reaction. n -DBCO, and then covalently linked with azide-modified siRNA through click chemistry to form siRNA-LA with one end being hydrophilic and the other end being hydrophobic. n The diblock conjugates then self-assemble in an aqueous environment through hydrophilic and hydrophobic forces to form spherical nucleic acid nanoparticles, namely siRNA micelles.
4. The preparation method according to claim 3, characterized in that: The azide-modified siRNA is prepared by modifying the 5' end of the sense strand of each siRNA with an azide group.
5. The preparation method according to claim 3, characterized in that: The steps include: Step 1: Using the natural small molecule LA as the basic unit, synthesize the lipoic acid material LA through condensation reaction n -DBCO; Step 2: LA n -DBCO and azide-modified siRNAs were covalently linked by click chemistry to form siRNA-LA with one end being hydrophilic and the other end being hydrophobic. n Diblock conjugates; Step 3: siRNA-LA n The diblock conjugates self-assemble in an aqueous environment to form spherical nucleic acid nanoparticles, namely siRNA micelles.
6. The preparation method according to claim 5, characterized in that: Step 2 includes: LA n -DBCO solution and azide-modified siRNA solution were mixed, placed at 4°C overnight, and then melted at 20°C. This reaction process was repeated to prepare siRNA-LA n Diblock conjugates.
7. The preparation method according to claim 5, characterized in that: Step 3 includes: siRNA-LA n The mixed solution of diblock conjugates was added dropwise into DEPC water, and siRNA-LA n The diblock conjugates form spherical nucleic acid micelles through hydrophilic and hydrophobic interactions.
8. Use of the siRNA micelles formed based on lipoic acid according to claim 1 or 2 in the preparation of drugs for treating brain diseases.
9. The use according to claim 8, characterized in that: The brain disease is glioma, and the siRNA in the siRNA micelle is a specific siRNA targeting PLK1 protein; Alternatively, the brain disease is Parkinson's disease, and the siRNA in the siRNA micelle is a specific siRNA targeting α-synuclein.
10. Use of the siRNA micelles formed based on lipoic acid according to claim 1 or 2 in the preparation of antioxidant drugs or anti-inflammatory drugs.
